Gonadorelin

What it is

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a 10-amino-acid hypothalamic peptide that controls pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The native molecule was first isolated and sequenced in the early 1970s by Andrew Schally and Roger Guillemin (work that contributed to their shared 1977 Nobel Prize in Physiology or Medicine).

Gonadorelin (Factrel) was FDA-approved in 1982 for evaluation of HPG axis function (specifically, evaluation of hypothalamic vs. pituitary causes of hypogonadism). It has decades of established clinical use. It is also approved for treatment of primary hypothalamic amenorrhea and for inducing ovulation in some specific contexts.

Off-label use of gonadorelin in modern practice has grown significantly in men’s hormone optimization, where it is increasingly used as an alternative to human chorionic gonadotropin (hCG) for maintaining testicular function during testosterone replacement therapy. This shift has been driven partly by hCG supply and cost issues and partly by gonadorelin’s favorable pharmacological profile.

Mechanism of action

Gonadorelin reproduces the action of native GnRH:

• Pituitary GnRH receptor activation: binds GnRH receptors on pituitary gonadotrophs, stimulating LH and FSH synthesis and release.
• LH and FSH release: downstream effects include LH stimulation of testicular Leydig cells (testosterone production in men) or ovarian theca/granulosa cells in women, and FSH effects on spermatogenesis or follicular development.
• Pulsatile vs. continuous administration paradox: pulsatile administration of gonadorelin (mimicking native pulsatile GnRH release) maintains and supports HPG axis function. Continuous administration paradoxically suppresses the HPG axis through receptor desensitization — this is the mechanism by which long-acting GnRH agonist depots (leuprolide, etc.) suppress sex hormone production for prostate cancer treatment.
• Short half-life: approximately 4 minutes, requiring frequent dosing or pulsatile delivery for sustained physiologic effect. This is why typical clinical use involves pulsatile or intermittent dosing schedules.

Research findings

Gonadorelin has decades of established clinical use:

Diagnostic use: historical FDA approval for evaluating HPG axis function. Gonadorelin stimulation tests can distinguish hypothalamic causes (intact pituitary response) from pituitary causes (no LH/FSH response) of hypogonadism.

Hypothalamic amenorrhea: pulsatile gonadorelin administration via portable infusion pumps has been used to restore reproductive function in women with hypothalamic causes of amenorrhea, including some causes of infertility.

Maintenance of testicular function during TRT: the contemporary primary clinical use. Testosterone replacement therapy suppresses endogenous LH production, leading to testicular atrophy and impaired spermatogenesis. Periodic gonadorelin (or hCG) administration provides exogenous LH-like stimulation that maintains testicular size and function.

Comparison to hCG: gonadorelin acts upstream (at the pituitary level) while hCG acts directly at testicular LH receptors. Both can support testicular function during TRT; gonadorelin has the advantage of activating endogenous physiologic pathways and may have less effect on estradiol conversion in some patients.

How we use it at The Tide

The primary use of gonadorelin in our practice is supporting testicular function in men on testosterone replacement therapy:

• Maintaining testicular size and reducing the testicular atrophy commonly seen with TRT
• Supporting fertility preservation for men on TRT who want to maintain reproductive capacity
• As an alternative to hCG when hCG availability is limited or cost-prohibitive
• Supporting recovery of HPG axis function in men discontinuing TRT

We coordinate with the patient’s TRT prescriber when relevant. Some patients receive their entire hormone optimization care through The Tide; others receive gonadorelin from us as an adjunct to TRT prescribed elsewhere.

Standard dosing: 100–300 mcg subcutaneously, 2–3 times weekly. The pulsatile-mimicking pattern (vs. continuous) is essential to avoid the paradoxical suppression seen with continuous GnRH agonist exposure.

Monitoring: testicular size assessment, semen analysis if fertility is a goal, and standard TRT monitoring (testosterone, estradiol, hematocrit).

Side effects and contraindications

Gonadorelin is well-tolerated at typical doses:

• Mild injection site reactions are most common
• Rare hypersensitivity reactions
• Possible mild headache
• Theoretical effects on estradiol conversion in men (typically minor)

Gonadorelin avoids some of the issues sometimes seen with hCG, including potentially less estradiol conversion and no concerns about hCG’s structural similarity to thyroid-stimulating hormone (which can rarely cause thyroid effects with hCG).

Contraindicated in:

• Pregnancy
• Active hormone-sensitive malignancies (prostate cancer in men, breast cancer)
• Untreated estrogen-sensitive conditions in women
• Hypersensitivity to gonadorelin or related compounds

What we don’t yet know

While gonadorelin has decades of established use, the optimal dosing patterns for testicular preservation during TRT — frequency, dose magnitude, and individual variability factors — are less rigorously characterized than the well-established protocols for diagnostic use. Long-term comparative outcomes between gonadorelin and hCG for TRT-related testicular preservation are not well established in head-to-head studies. The role of gonadorelin in supporting recovery of HPG function after long-term TRT discontinuation is an area of practical importance with limited formal study. We present gonadorelin to patients as an established peptide pharmaceutical with decades of clinical experience, used appropriately for specific indications in men’s health and select reproductive scenarios.